Rapid, living evidence-based points: methods and processes of development_Chinese Journal of Evidence-Based Medicine

Authors：

TIAN Chen ^1,2,3,4 , SUN Mingyao ^3,4,5 , LI Ying ^1,2,3,4 , PAN Bei ^1,2,3,4,6 , ZHOU Qi ^3,4,6 , ZHAO Chen ⁷ , LIU Yu ^7,8 , LI Ling ⁹ , LIAO Xing ⁷ , DENG Hongyong ¹⁰ , WU Darong ¹¹ , JIN Yinghui ¹² , SHANG Hongcai ¹³ , TIAN Jinhui ^3,4,6 , CHEN Yaolong ^3,4,6 , YANG Kehu ^3,4,6 , LIU Jie ^8,14 , HUANG Luqi ⁸ ,  GE Long ^1,2,3,4

1. Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou 730000, P. R. China;
2. Department of Social Science and Health Management, School of Public Health, Lanzhou University, Lanzhou 730000, P. R. China;
3. Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou 730000, P. R. China;
4. WHO Collaborating Center for Guideline Implementation and Knowledge Translation, Lanzhou 730000, P. R. China;
5. Evidence-Based Nursing Center, School of Nursing, Lanzhou University, Lanzhou 730000, P. R. China;
6. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, P. R. China;
7. Institute of Basic Research in Clinical, China Academy of Chinese Medical Sciences, Beijing 100700, P. R. China;
8. China Center for Evidence-Based Traditional Chinese Medicine, Beijing 100700, P. R. China;
9. Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
10. TCM Health Collaborative Innovation Center, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P. R. China;
11. The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine (Guangdong Hospital of Traditional Chinese Medicine), Guangzhou 510120, P. R. China;
12. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, P. R. China;
13. Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, P. R. China;
14. Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100700, P. R. China;

Corresponding author：

GE Long, Email: gelong2009@163.com

Keywords：

Rapid living evidence-based points; Methods and processes; Evidence-based medicine; Clinical practice guidelines

DOI：

10.7507/1672-2531.202301029

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Rapid, living evidence-based points, as a new model promoting the rapid translation of evidence, aim to integrate the current best evidence, clinical status, public/patient preferences and values, and provide concise and practical guidance rapidly to important questions concerned in clinical medicine and public health. This paper introduces the methodological framework for the development of "Rapid, Living Evidence-Based Points" from 4 aspects: initiation and planning, evidence search and review, development, update, publication and dissemination of evidence-based points, in order to provide a reference for domestic scholars in developing rapid, living evidence-based points.

Citation： TIAN Chen, SUN Mingyao, LI Ying, PAN Bei, ZHOU Qi, ZHAO Chen, LIU Yu, LI Ling, LIAO Xing, DENG Hongyong, WU Darong, JIN Yinghui, SHANG Hongcai, TIAN Jinhui, CHEN Yaolong, YANG Kehu, LIU Jie, HUANG Luqi, GE Long. Rapid, living evidence-based points: methods and processes of development. Chinese Journal of Evidence-Based Medicine, 2023, 23(4): 450-456. doi: 10.7507/1672-2531.202301029 Copy

1.	Qaseem A, Yost J, Forciea MA, et al. The development of living, rapid practice points: summary of methods from the scientific medical policy committee of the American college of physicians. Ann Intern Med, 2021, 174(8): 1126-1132.
2.	Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19. rapid, living practice points from the American college of physicians (version 1). Ann Intern Med, 2021, 174(2): 229-236.
3.	Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19. rapid, living practice points from the American college of physicians (version 2). Ann Intern Med, 2021, 174(5): 673-679.
4.	Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Update alert 2: should remdesivir be used for the treatment of patients with COVID-19. rapid, living practice points from the American college of physicians (version 2). Ann Intern Med, 2021, 174(12): W116-W117.
5.	Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19. rapid, living practice points from the American college of physicians (version 2, update alert 3). Ann Intern Med, 2022, 175(5): W55-W57.
6.	Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. What is the antibody response and role in conferring natural immunity after SARS-CoV-2 Infection. rapid, living practice points from the American college of physicians (version 1). Ann Intern Med, 2021, 174(6): 828-835.
7.	Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. What is the antibody response and role in conferring natural immunity after SARS-CoV-2 Infection. rapid, living practice points from the American college of physicians (version 2). Ann Intern Med, 2022, 175(4): 556-565.
8.	陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则(2022版). 中华医学杂志, 2023, 176(1): 92-104.
9.	GIN. WHO and rapid advice guidelines: history and future directions.
10.	World Health Organization. WHO handbook for guideline development (2nd edition).
11.	El Mikati IK, Khabsa J, Harb T, et al. A framework for the development of living practice guidelines in health care. Ann Intern Med, 2022, 175(8): 1154-1160.
12.	Alper BS, Haynes RB. EBHC pyramid 5. 0 for accessing preappraised evidence and guidance. Evid Based Med, 2016, 21(4): 123-125.
13.	Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022).
14.	Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol, 2011, 64(4): 383-394.
15.	Balshem H, Helfanda M, Schunemann HG, 等. GRADE指南: Ⅲ. 证据质量分级. 中国循证医学杂志, 2011, 11(4): 451-455.
16.	Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019, 366: l4898.
17.	Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 2016, 355: i4919.
18.	Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
19.	杨楠, 赵巍, 潘旸, 等. 针对临床实践指南科学性、透明性和适用性的评级工具研发. 中华医学杂志, 2022, 102(30): 2329-2337.
20.	Jaeschke R, Singer J, Guyatt GH. Measurement of health status. ascertaining the minimal clinically important difference. Control Clin Trials, 1989, 10(4): 407-415.
21.	Scottish Intercollegiate Guidelines Network. A handbook for patient and careers representatives.

1. Qaseem A, Yost J, Forciea MA, et al. The development of living, rapid practice points: summary of methods from the scientific medical policy committee of the American college of physicians. Ann Intern Med, 2021, 174(8): 1126-1132.
2. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19. rapid, living practice points from the American college of physicians (version 1). Ann Intern Med, 2021, 174(2): 229-236.
3. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19. rapid, living practice points from the American college of physicians (version 2). Ann Intern Med, 2021, 174(5): 673-679.
4. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Update alert 2: should remdesivir be used for the treatment of patients with COVID-19. rapid, living practice points from the American college of physicians (version 2). Ann Intern Med, 2021, 174(12): W116-W117.
5. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19. rapid, living practice points from the American college of physicians (version 2, update alert 3). Ann Intern Med, 2022, 175(5): W55-W57.
6. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. What is the antibody response and role in conferring natural immunity after SARS-CoV-2 Infection. rapid, living practice points from the American college of physicians (version 1). Ann Intern Med, 2021, 174(6): 828-835.
7. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. What is the antibody response and role in conferring natural immunity after SARS-CoV-2 Infection. rapid, living practice points from the American college of physicians (version 2). Ann Intern Med, 2022, 175(4): 556-565.
8. 陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则(2022版). 中华医学杂志, 2023, 176(1): 92-104.
9. GIN. WHO and rapid advice guidelines: history and future directions.
10. World Health Organization. WHO handbook for guideline development (2nd edition).
11. El Mikati IK, Khabsa J, Harb T, et al. A framework for the development of living practice guidelines in health care. Ann Intern Med, 2022, 175(8): 1154-1160.
12. Alper BS, Haynes RB. EBHC pyramid 5. 0 for accessing preappraised evidence and guidance. Evid Based Med, 2016, 21(4): 123-125.
13. Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022).
14. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol, 2011, 64(4): 383-394.
15. Balshem H, Helfanda M, Schunemann HG, 等. GRADE指南: Ⅲ. 证据质量分级. 中国循证医学杂志, 2011, 11(4): 451-455.
16. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019, 366: l4898.
17. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 2016, 355: i4919.
18. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
19. 杨楠, 赵巍, 潘旸, 等. 针对临床实践指南科学性、透明性和适用性的评级工具研发. 中华医学杂志, 2022, 102(30): 2329-2337.
20. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. ascertaining the minimal clinically important difference. Control Clin Trials, 1989, 10(4): 407-415.
21. Scottish Intercollegiate Guidelines Network. A handbook for patient and careers representatives.

Chinese Journal of Evidence-Based Medicine

Rapid, living evidence-based points: methods and processes of development

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content